Pre-Operative Measures of Systemic Inflammation Predict Survival After Surgery for Primary Lung Cancer

IF 3.3 3区 医学 Q2 ONCOLOGY
Marcus Taylor , Matt Evison , Sarah Michael , Emmanuel Obale , Nils C. Fritsch , Udo Abah , Matthew Smith , Glen P. Martin , Michael Shackcloth , Felice Granato , Stuart W. Grant , Northwest Thoracic Surgery Collaborative (NWTSC)
{"title":"Pre-Operative Measures of Systemic Inflammation Predict Survival After Surgery for Primary Lung Cancer","authors":"Marcus Taylor ,&nbsp;Matt Evison ,&nbsp;Sarah Michael ,&nbsp;Emmanuel Obale ,&nbsp;Nils C. Fritsch ,&nbsp;Udo Abah ,&nbsp;Matthew Smith ,&nbsp;Glen P. Martin ,&nbsp;Michael Shackcloth ,&nbsp;Felice Granato ,&nbsp;Stuart W. Grant ,&nbsp;Northwest Thoracic Surgery Collaborative (NWTSC)","doi":"10.1016/j.cllc.2024.04.018","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Measures of systemic inflammation (MSIs) have been developed and shown to help predict prognosis in patients with lung cancer. However, studies investigating the impact of MSIs on outcomes solely in cohorts of patients undergoing curative-intent resection of NSCLC are lacking. In the era of individualized therapies, targeting inflammatory pathways could represent a novel addition to the armamentarium of lung cancer treatment.</p></div><div><h3>Methods</h3><p>A multicentre retrospective review of patients who underwent primary lung cancer resection between 2012 and 2018 was undertaken. MSIs assessed were neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic immune inflammation index (SII), advanced lung cancer inflammation index (ALI), prognostic nutritional index (PNI) and haemoglobin albumin lymphocyte platelet (HALP) score. Cox regression analysis was performed to assess the impact of MSIs on overall survival.</p></div><div><h3>Results</h3><p>A total of 5029 patients were included in the study. Overall 90-day mortality was 3.7% (n = 185). All MSIs were significantly associated with overall survival on univariable analysis. After multivariable Cox regression analyses, lower ALI (expressed as a continuous variable) (HR 1.000, 95% CI 1.000-1.000, <em>P</em> = .049) and ALI &lt;366.43 (expressed as a dichotomous variable) (HR 1.362, 95% CI 1.137-1.631, <em>P</em> &lt; .001) remained independently associated with reduced overall survival.</p></div><div><h3>Conclusions</h3><p>MSIs have emerged in this study as potentially important factors associated with survival following lung resection for NSCLC with curative intent. In particular, ALI has emerged as independently associated with long-term outcomes. The role of MSIs in the clinical management of patients with primary lung cancer requires further investigation.</p></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424000779","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Measures of systemic inflammation (MSIs) have been developed and shown to help predict prognosis in patients with lung cancer. However, studies investigating the impact of MSIs on outcomes solely in cohorts of patients undergoing curative-intent resection of NSCLC are lacking. In the era of individualized therapies, targeting inflammatory pathways could represent a novel addition to the armamentarium of lung cancer treatment.

Methods

A multicentre retrospective review of patients who underwent primary lung cancer resection between 2012 and 2018 was undertaken. MSIs assessed were neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic immune inflammation index (SII), advanced lung cancer inflammation index (ALI), prognostic nutritional index (PNI) and haemoglobin albumin lymphocyte platelet (HALP) score. Cox regression analysis was performed to assess the impact of MSIs on overall survival.

Results

A total of 5029 patients were included in the study. Overall 90-day mortality was 3.7% (n = 185). All MSIs were significantly associated with overall survival on univariable analysis. After multivariable Cox regression analyses, lower ALI (expressed as a continuous variable) (HR 1.000, 95% CI 1.000-1.000, P = .049) and ALI <366.43 (expressed as a dichotomous variable) (HR 1.362, 95% CI 1.137-1.631, P < .001) remained independently associated with reduced overall survival.

Conclusions

MSIs have emerged in this study as potentially important factors associated with survival following lung resection for NSCLC with curative intent. In particular, ALI has emerged as independently associated with long-term outcomes. The role of MSIs in the clinical management of patients with primary lung cancer requires further investigation.

术前全身炎症指标可预测原发性肺癌手术后的存活率
已开发出全身炎症指标(MSIs),并证明有助于预测肺癌患者的预后。然而,目前还缺乏研究,仅针对接受NSCLC根治性切除术的患者群体调查MSIs对预后的影响。在个体化治疗时代,靶向炎症通路可能成为肺癌治疗的新手段。我们对2012年至2018年间接受原发性肺癌切除术的患者进行了多中心回顾性研究。评估的MSI包括中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、全身免疫炎症指数(SII)、晚期肺癌炎症指数(ALI)、预后营养指数(PNI)和血红蛋白白蛋白淋巴细胞血小板(HALP)评分。为评估 MSIs 对总生存期的影响,进行了 Cox 回归分析。研究共纳入了 5029 名患者。90天总死亡率为3.7%(n = 185)。在单变量分析中,所有MSI都与总生存率有明显相关性。经过多变量 Cox 回归分析,较低的 ALI(以连续变量表示)(HR 1.000,95% CI 1.000-1.000,=0.049)和 ALI <366.43(以二分变量表示)(HR 1.362,95% CI 1.137-1.631,<0.001)仍与总生存率降低独立相关。本研究发现,MSIs可能是影响NSCLC根治性肺切除术后生存率的重要因素。其中,ALI与长期预后密切相关。MSIs在原发性肺癌患者临床治疗中的作用还需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical lung cancer
Clinical lung cancer 医学-肿瘤学
CiteScore
7.00
自引率
2.80%
发文量
159
审稿时长
24 days
期刊介绍: Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信